Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
absent, achievedin, addicted, addiction, adult, antileukemic, Antitumor, apoptotic, began, Boston, correlated, cytarabine, deliverable, demonstratedin, Diffuse, DLBCL, Dundee, equipment, experimental, family, Herceptin, higher, leukemogenic, lineage, Lymphoma, mechanistically, medicine, metabolic, Mixed, MM, MYC, nonrefundable, oncogenic, partby, pathway, plant, potentin, promulgated, provisional, rapid, regression, revealed, sensitivity, spanned, standalone, stratification, stratified, sublicensee, submicromolar, tolerability, tolerated, trastuzumab, vitroandin, vivoin, vivowith, xenograft
Removed:
amortization, ceased, confer, enabling, gBRCA
Filing tables
Filing exhibits
Related press release
CYCC similar filings
Filing view
External links